Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in ...

INR:4518. new edition bet awards performance How to prevent and treat the return of Ebola? Can it be cured? FDA updates ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

The United States will try to defend its title when the 2025 IIHF World Junior Championship begins Thursday in Ottawa. The United States won the 2024 WJC, defeating Sweden 6-2 in the gold medal ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Prosper Junior Bakiny (Novo Nordisk): Various factors can cause an end-of-the-year stock market rally, including optimism about the coming year. It's hard to predict which companies -- if any ...